我爱我家

China releases first ecological assessment of Xisha, Zhongsha, Nansha Qundao islands and reefs_我的网站

一 |     

    An aerial view of the Xisha Qundao Photo: VCGChina's Ministry of Natural Resources on Friday for the first time released a concentrated assessment of the ecological conditions of islands and reefs in the Xisha, Zhongsha and Nansha Qundao island groups, presenting a detailed picture of nine representative islands and reefs ahead of China's 2026 National Ecology Day, which falls on August 15, China Central Television (CCTV) News reported Friday.
The assessment showed that the nine islands and reefs are generally in good ecological condition, although their ecosystems vary significantly from one location to another. The findings are expected to provide a scientific basis for more targeted conservation and management of different types of island and reef ecosystems.
Coral reef ecosystems in the Xisha Qundao have shown encouraging signs of recovery. The overall ecological conditions of four atolls, including the Beijiao, the Yongle Atoll, Yuzhuo Jiao and Langhua Jiao, of the Xisha Qundao, were rated as good.
Although live coral cover remains relatively low as a result of the large-scale coral bleaching event in 2020 and outbreaks of crown-of-thorns starfish since 2018, the reefs have recorded a high level of hard-coral recruitment, indicating strong and continued recovery, CCTV reported. 
Coral reefs are one of the best natural indicators of seawater quality, and are also a key foundation for marine biodiversity, Chen Xiangmiao, director of the World Navy Research Center at the National Institute for South China Sea Studies, told the Global Times on Friday. 
Huangyan Dao, meanwhile, stands out as a rare "biological gene bank" in the central South China Sea. Surveys recorded 135 species of reef-building corals around Huangyan Dao. Seagrass beds covering about 1.85 square kilometers were found distributed across its lagoon, with an average coverage of 19.2 percent. Live coral cover within the protected area has reached 38.8 percent.
The waters are also home to a range of rare and protected species, including green sea turtles, hawksbill turtles, giant clams and trumpet tritons, according to the assessment.
Chen said Huangyan Dao's coral reef ecosystem provides stable and diverse habitats for a wide range of marine species. With relatively limited development, its coral reefs function much like an underwater forest, offering feeding, shelter and breeding grounds for rare species such as sea turtles and giant clams. Its shallow lagoon and seagrass beds further enrich the variety of habitats, allowing different species to coexist and supporting a high level of biodiversity.
Ecological conditions among the Nansha Islands and reefs showed greater differences. While the overall condition remained good, some individual reef ecosystems have suffered serious degradation, according to CCTV News. 
Xianbin Jiao and Niu'e Jiao were assessed as being in good ecological condition, with live coral coverage reaching 24.7 percent and 37.7 percent, respectively.
By contrast, the ecosystems of Tiexian Jiao and Ren'ai Jiao have deteriorated significantly.
At Tiexian Jiao, outbreaks of crown-of-thorns starfish, tropical cyclones and foreign human activities, particularly continued construction by the Philippines on Zhongye Dao, have contributed to ecological damage. The area covered by live corals has fallen by nearly 70 percent compared with 2016. 
At Ren'ai Jiao, the long-term presence of a foreign military vessel illegally grounded there has caused pollution discharge, waste accumulation and fishing-net entanglement, according to the assessment. Live coral coverage has declined sharply, while both coral growth and natural recovery have been inhibited, according to CCTV. 
China has also continued to increase investment in marine ecological conservation and restoration in the South China Sea.
According to one of the released reports on ecological protection and restoration, natural resources, marine and forestry authorities at various levels in the South China Sea region implemented 66 marine ecological restoration projects in 2025, with total investment approaching 5 billion yuan ($741.5 million). 
China has long made the protection of the South China Sea's marine environment a priority, with particular attention to coral reefs, fishery resources and water quality, Chen said, adding that the good ecological conditions found at these islands under China's management show that conservation and restoration efforts have produced tangible results. 
During the 14th Five-Year Plan period (2021-25), a total of 262 marine ecological protection and restoration projects were carried out, involving more than 21.3 billion yuan in investment.
By the end of 2025, approximately 2.66 million hectares of marine ecological conservation redline areas and about 7 million hectares of marine nature reserves had been designated in the South China Sea region.
。    AI设计的口服减重药有望2028年底上市 钱塘区生物医药产值已突破500亿元 近日，杭州德睿智药科技有限公司宣布完成累计5200万美元B轮融资。2026年1月，杭州医药港，德睿智药一款名叫MDR-001的口服减重药，以令全球医药界瞩目的速度，启动Ⅲ期临床试验，成为国内首个进入临床Ⅲ期的AI小分子新药。这家仅40多人的公司，把一款一类创新药从立项到推进至Ⅲ期临床的时间，压缩到了4.5年。

二 | 而传统同行完成同样的路程，通常需要8到12年。不用“大海捞针”了2021年初，85后海归博士牛张明，带着计算机和生物制药2个硕士学位、5种AI算法语言，在钱塘区成立了德睿智药。当时，他就想好了：“要走一条和传统制药完全不同的路。

三 | ”传统新药研发有多难？业内有个“双十定律”，即成功研发一款创新药，平均需要10年的时间和10亿美元的投入。面对超过10的60次方级别、近乎无限的成药化学空间，科学家们只能靠经验和反复试错，如同在茫茫大海里捞针。

四 | 牛张明说：“过去的药物发现，靠大量实验、反复试错，不仅耗时间，成功率也低。现在用上AI，好比给每位科学家配了一个‘超级大脑’做助手。

五 | ”2026年，德睿智药基于MDR-001的研发流程，搭建起了由多智能体驱动的全链条AI制药引擎MAP。这个平台覆盖靶点发现、分子设计、多目标优化、实验验证及临床试验全链条。

六 | “药物分子就像精密的拼图，每个片段都决定着药效和安全性。以往，这全靠科研人员的经验和反复试错。

七 | ”牛张明解释，“MAP能通过学习海量已知药物的成功与失败案例，自动预测分子片段的性质，大幅减少试错成本、缩短研发周期。”他打了一个比方：“你可以把它想象成一位高效且永不疲倦的‘分子组装专家’，在虚拟世界里高速筛选，帮研发人员提前排除大量‘错误选项’。”药物研发，就这样从“大海捞针”变成了“高清导航”。口服减重新药将于2028年底上市MDR-001是一款GLP-1（胰高血糖素样肽-1）受体激动剂，与市面上常见的减肥注射剂最大的不同在于，它可以口服。“我们立项时，口服GLP-1还没有出现。口服小分子药物的依从性更高，患者不需要消毒针头注射、不需要低温冷藏保存，使用更方便；在某些适应证上疗效甚至优于注射剂型。”牛张明说。

八 | 在MDR-001项目中，团队仅耗时8个月、实际仅合成80个小分子，就获得了高质量的临床前候选药物。

九 | 从立项到推进至Ⅲ期临床研究，整体仅耗时4.5年，单产品累计研发投入控制在约2300万美元。

十 | 对比传统同类药物的研发周期和投入，这组数字可以称得上是“奇迹”了。“从临床前阶段来看，AI制药平台可节省50%至70%的研发成本，并将研发周期缩短50%以上。”牛张明说。目前，MDR-001的Ⅲ期临床进展顺利，已在国内完成760名受试者招募，合作临床中心近50家。在已完成的IIb期临床试验中，317名平均体重约90公斤的受试者在用药24周后，体重平均降幅达10.3%，因不良反应导致的停药率仅为0.8%。如果一切顺利，这款“钱塘智造”的口服减重新药，有望于2028年底或2029年初上市。

Current article:http://6n7sxd.yofateeikengyeche.cfd/zl3zy/20260826/4245.html

Published on:00:08:38